-

KORU Medical Appoints Chris Pazdan as Vice President of Quality Assurance and Regulatory Affairs

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced the appointment of Chris Pazdan as the Company's new Vice President of Quality Assurance and Regulatory Affairs. Mr. Pazdan will be responsible for all quality assurance and regulatory affairs as the Company continues to build out a robust Quality Management System and a regulatory strategy to meet evolving global standards.

"Chris has the right mix of strategic, operational, and corporate quality and regulatory skills to bring to this role at KORU Medical," said Linda Tharby, Chief Executive Officer. "His proven track record of developing and leading strategy, a focus on execution and building strong teams will be a valuable asset to KORU Medical as we advance our quality capabilities to meet the needs of our biopharmaceutical customers and support our growth strategy.

Chris Pazdan joins the KORU Medical team with over 16 years of relevant experience in quality assurance and regulatory affairs within the medical technology industry. Most recently, Mr. Pazdan spent over three years at Hillrom, a global medical technology company, where he held the role of Vice President, Quality Assurance, where he led all quality functions for the largest manufacturing division. He also served as the Vice President, Quality Assurance and Regulatory Affairs, where he was responsible for enterprise-wide Design Assurance, Supplier Quality Assurance, Project Management Office, and Software. Prior to Hillrom, Mr. Pazdan also worked at Abbott Laboratories, Becton Dickinson, Wockhardt and Rexam Pharma. Mr. Pazdan received his bachelor's degree in engineering from the University of Illinois at Urbana-Champaign. He is an ASQ Certified Six Sigma Black Belt, ASQ Certified Quality Engineer, and an ASQ Certified Quality Auditor.

About KORU Medical Systems

KORU Medical Systems develops, manufactures, and commercializes innovative and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing and HIgH-Flo Subcutaneous Safety Needle Sets. These devices are used for infusions administered in the home and alternate care settings. For more information, please visit www.korumedical.com.

Contacts

Investor Contact:
Greg Chodaczek
347-620-7010
investor@korumedical.com

KORU Medical Systems

NASDAQ:KRMD

Release Versions

Contacts

Investor Contact:
Greg Chodaczek
347-620-7010
investor@korumedical.com

More News From KORU Medical Systems

KORU Medical Systems to Participate in the 8th Annual Lake Street Best Ideas Growth Conference

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will be participating in investor meetings at the 8th Annual Lake Street Best Ideas Growth Conference in New York on Thursday, September 12, 2024. About KORU Medical Systems KORU Med...

KORU Medical Systems, Inc. Announces 2024 Q2 Financial Results, a Record Quarter With 22% Revenue Growth; Raises Full Year 2024 Guidance

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2024 and raised full year 2024 revenue and gross margin guidance. Financial Highlights Second quarter 2024 net revenues of $8.4 million, a 22%...

KORU Medical Systems to Participate in the Canaccord Genuity 44th Annual Growth Conference

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will participate in the Canaccord Genuity 44th Annual Growth Conference on August 14, 2024. KORU Medical's management is scheduled to present at the Canaccord Genuity 44th Annual Gro...
Back to Newsroom